Zu den Inhalten springen


Kontakt | English | Sitemap
  • Geschichte

| Home > Zentren > Onkologisches Zentrum > Klinik und Poliklinik für Strahlentherapie und Radioonkologie > Labor für Strahlenbiologie und Experimentelle Radioonkologie > Publikationen



Parplys AC, Petermann E, Petersen C, Dikomey E, Borgmann K. DNA double-strand breaks are the irradiation-induced lesions that interfere most strongly with replication forks. Radiother Oncol. In press.

Reuther S, Metzke E, Bonin M, Petersen C, Dikomey E, Raabe A. No effect of transforming growth factor ß1 promoter polymorphism C-509T on TGFB1 gene expression, protein secretion, or cellular radiosensitivity. Int J Radiat Oncol Biol Phys, in press.

Rieckmann T., Nitsch L., Rohaly G., Petersen C., Dikomey E., Dornreiter I., Dahm-Daphi J. Inhibition of wtp53 by dominant-negative p53 mutants stimulates homologous recombination exclusively by cell cycle regulation. Oncogene in press.

Köcher S., Rieckmann T., Rohaly G., Mansour W., Dikomey E., Dornreiter I., Dahm-Daphi J. Dissecting the requirement of ATM and Artemis for homologous recombination in S and G2 phase. Nuclear Acids Res, in rev.

Raabe A, Derda K, Reuther S, Szymczak S, Borgmann K, Hoeller U, Ziegler A, Petersen C, Dikomey E. Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy. Radiother Oncol, in press.

Mansour WY, Rieckmann T, Dörk T., Koecher S., Baumann M, Petersen C., K. Borgmann, Kasten-Pisula, Dikomey E., Dahm-Daphi J. miR421-mediated ATM-depletion leads to a pronounce DNA repair defect and clinically manifest tumor radiosensitivity. Radiother & Oncol, in press.

Saker J, Zenker M, Heldt JM, Pietzsch HJ, Kriegs M, Petersen C, Baumann M, Steinbach J, Dikomey E, Kasten-Pisula U. Inactivation of HNSCC cells by 90Y-labeled Cetuximab strictly depends on the number of induced DNA double-strand breaks. J Nuclear Medicine, in press.

Jung H, Beck-Bornholdt H-P, Svoboda V, Alberti W, Herrmann T. Late complications after radiotherapy for prostate cancer. Strahlenther Oncol, 2012; 188:965-974

Dikomey E, Dahm-Daphi J, Distel L. Prädiktion von Normal- und Tumorreaktion nach Strahlentherapie. Strahlenther Onkol 2012; 188:304-307

Mund A, Schubert T, Staege H, Kinkley S, Reumann K, Kriegs M, Fritsch L, Battisti V, Ait-Si-Ali S, Hoffbeck AS, Soutoglou E, Will H. SPOC1 modulates DNA repair by regulating key determinants of chromatin compaction and DNA damage response. Nucl Acids Res 2012, accepted.

Tennstedt P, Fresow R, Simon R, Marx A, Terraccian L, Petersen C, Sauter G, Dikomey E, Borgmann K. RAD51 over-expression is a negative prognostic marker for colorectal adenocarcinoma. Int J. Cancer 2012, in press.

Dikomey E., Borgmann K., Kriegs M., Mansour W., Rieckmann T. Petersen C. Strahlenempfindlichkeit von Tumorzellen. In: Onkologie: Grundlagen, Diagnostik, Therapie, Entwicklungen (Hrsg. Zeller, zur Hausen), ecomed, München, 2012, pp1-19.

Rieckmann T, Tribius S, Grob T, Petersen C, Dikomey E, Kriegs M. HNSCC cell lines double positive for HPV and p16 possess a higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol, accepted

Andreassen CN, Dikomey E, Parliament M, West CML. Will SNPs be useful predictors of normal tissue radiosensitivity in the future? Highlights from a scientific debate held at the ESTRO 31 meeting. Radiother Oncol, in press.

Clauditz TS, Wang CJ, Gontarewicz A, Blessmann M, Tennstedt P, Borgmann K, Tribius S, Sauter G, Dalchow C, Knecht R, Münscher A, Wilczak W. Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck. J Oral Pathol Med. 2012 May 29. doi: 10.1111/j.1600-0714.2012.01178.x. [Epub ahead of print]

Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, Simon R, Mayer PS, Schumacher U, Grupp K, Izbicki JR, Pantel K, Dikomey E, Korbel JO, Plass C, Sauter G, Schlomm T, Minner S. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Modern Pathology 2012, in press



Zschenker O, Raabe A, Böckelmann IK, Borstelmann S, Szymczak, Wellek S, Rades D, Hoeller U, Ziegler A, Dikomey E, Borgmann K, Association of single nucleotide polymorphisms in ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with clinical and cellular radiosensitivity. Radiother Oncol 2010; 2010;97:26-32

El-Awady RA, Saleh EM, Dahm-Daphi J, Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil? Anti-Cancer Drugs 2010; 21:277-287

Storch K, Eke I, Borgmann K, Krause M, Richter C, Becker K, Schröck E, Cordes N, Three-dimensional cell growth confers radioresistance by chromatin density. Cancer Research 2010; 2010;70:3925-3934

Borgmann K, Raabe A, Reuther S, Szymczak S, Schlomm T, Isbarn H, Gomolka M, Busjahn A, Bonin M, Ziegler A, Dikomey E, The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer. Radiotherapy & Oncology 2010; 96:19-24

Mansour WY, Rhein T, Dahm-Daphi J, The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic Acids Research, 2010;38:6065-6077

Kriegs M, Kasten-Pisula, Rieckmann T, Holst K, Saker J, Dahm-Daphi J, Dikomey E, The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair 2010, 2010;9:889-897

Steinberg F, Gerber SD, Rieckmann T, Trueb B. Rapid fusion and syncytium formation of heterologous cells upon expression of the FGFRL1 receptor. J Biol Chem 2010, 285:37704-37715.

Dikomey E. Determination of DNA damage in vitro. Nuklearmedizin. 2010;49:S64-S68.

Brassat U, Balabanov S, Bali D, Dierlamm J, Braig M, Hartmann U, Sirma H, Gunes C, Wege H, Fehse B, Gontarewicz A, Dikomey E, Borgmann K, Brummendorf TH. Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells. Exp Hematol 2011;39:66-76.

Tribius S., Ihloff AS, Rieckmann T, Petersen C, Hoffmann M, Impact of HPV status on treatment of squamous cell cancer of the oropharynx: What we know and what we need to know. Cancer Letters 2011; 304:71-79.

Kachnic LA, Li L, Fournier L, Ferraiolo N, Dahm-Daphi J, Borgmann K, Willers H. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. Cancer Letters 2011, 305:86-93.

Meyer-Schwesinger C., Lange C., Bröcker V., Agustian PA., Lehmann U., Raabe A., Brinkmeyer M., Kobayashi E., Schiffer M.,_ Büsche G., Kreipe HH:, Thaiss F, Becker JU, Bone marrow–derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats. Am J Pathol 2011, 178; 494-499.

Kasten-Pisula U, Saker J, Eicheler W, Krause M, Yaromina A, Meyer-Staeckling S, Scherkl B, Kriegs M, Brandt B, Petersen C, Baumann M, Dikomey E. Cellular and tumour radiosensitivity is correlated to EGFR protein expression level in tumours without egfr amplification. Int J Radiat Oncol Biol Phys 2011, 80:1181-1188.

Moyal L, Lerenthal Y, Gana-Weisz M, Mass G, So S, Wang SH, Eppink B, Chung YM, Shalev G, Shema E, Shkedy D, Smorodinsky N, van Vliet N, Kuster B, Mann M, Ciechanover A, Dahm-Daphi J, Kanaar R, Hu MCT, Chen DJ, Oren M, Shiloh Y, Requirement of ATM-Dependent Monoubiquitylation of Histone H2B for Timely Repair of DNA Double-Strand Breaks. Molecular Cell 2011, 41; 529-542.

Myllynen L, Rieckmann T, Dahm-Daphi J, Kasten-Pisula U, Petersen C, Dikomey E, Kriegs M. In tumour cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. Radiother Oncol. 2011, 101:147-151.

Wang M., Morsbach F., Sander D., Gheorghiu L., Nanda A., Benes C., Kriegs M., Dikomey E., Dahm-Daphi J., Settleman J., Willers H. Inhibition of the EGFR sensitizes NSCLC cells to radiation and etoposide via DNA double-strand break inducible senescence. Cancer Res, 2011; 71:6261-6269.

Dikomey E., Borgmann K., Raabe A., Reuther S. Individuelle Strahlenempfindlichkeit: Molekulare Mechanismen der Zellinaktivierung. Ver. Strahlenschutzkommission, Band 66: 96-110.

Seitenanfang    Seite drucken

© Universitätsklinikum Hamburg-Eppendorf, Impressum
Letzte Änderung: Sebastian Reuther, 19.11.2012